Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Impact of early cART in the gut during acute HIV infection
Claire Deleage, … , Jacob D. Estes, on behalf of the RV254/SEARCH 010 and RV304/SEARCH 013 Study Groups
Claire Deleage, … , Jacob D. Estes, on behalf of the RV254/SEARCH 010 and RV304/SEARCH 013 Study Groups
Published July 7, 2016
Citation Information: JCI Insight. 2016;1(10):e87065. https://doi.org/10.1172/jci.insight.87065.
View: Text | PDF
Research Article AIDS/HIV

Impact of early cART in the gut during acute HIV infection

  • Text
  • PDF
Abstract

Early after HIV infection there is substantial depletion of CD4+ T cells in the gastrointestinal (GI) tract lamina propria (LP), with associated epithelial barrier damage, leading to microbial translocation and systemic inflammation and immune activation. In this study, we analyzed these early events in the GI tract in a cohort of Thai acute HIV-infected patients and determined the effect of early combination antiretroviral treatment (cART). HIV-uninfected and chronically and acutely HIV-infected patients at different Fiebig stages (I–V) underwent colonic biopsies and then received cART. Immunohistochemistry and quantitative image analysis were performed on cross-sectional and longitudinal colon biopsy specimens (day 0 to week 96) to measure GI tract damage (infiltration of polymorphonuclear cells), inflammation (Mx1, TNF-α), immune activation (Ki-67), and the CD4+ T cell population in the LP. The magnitude of GI tract damage, immune activation, and inflammation was significantly increased, with significantly depleted CD4+ T cells in the LP in all acutely infected groups prior to cART compared with HIV-uninfected control participants. While most patients treated during acute infection resolved GI tract inflammation and immune activation back to baseline levels after 24 weeks of cART, most acutely infected participants did not restore their CD4+ T cells after 96 weeks of cART.

Authors

Claire Deleage, Alexandra Schuetz, W. Gregory Alvord, Leslie Johnston, Xing-Pei Hao, David R. Morcock, Rungsun Rerknimitr, James L.K. Fletcher, Suwanna Puttamaswin, Nittaya Phanuphak, Robin Dewar, Joseph M. McCune, Irini Sereti, Merlin Robb, Jerome H. Kim, Timothy W. Schacker, Peter Hunt, Jeffrey D. Lifson, Jintanat Ananworanich, Jacob D. Estes, on behalf of the RV254/SEARCH 010 and RV304/SEARCH 013 Study Groups

×

Figure 7

Effect of combined antiretroviral therapy on the CD4+ T cell population in the lamina propria of acute HIV-infected participants.

Options: View larger image (or click on image) Download as PowerPoint
Effect of combined antiretroviral therapy on the CD4+ T cell population ...
Sigmoid biopsies were stained for CD4 and CD68/CD163. The CD4+ T cell population was determined by subtraction of the myeloid population from the total CD4+ cell population. The percentage area of the lamina propria that stained for CD4+ T cells was quantified in Fiebig I/II (FI/II) participants (week 0, n = 19; week 24, n = 14; week 96, n = 7) (A) and in Fiebig III–V (FIII+) patients (week 0, n = 22; week 24, n = 14; week 96, n = 12) (B) at the first visit (week 0) and again at 24 weeks and 96 weeks after treatment. The dashed lines represent the median of CD4+ T cells in healthy control participants (gray, n = 10) and in chronic HIV-infected patients (red, n = 17). Each symbol represents a patient. FII is distinguishable from FI by the light-blue colored symbols, and FIV/V is distinguishable from FIII by the dark-blue colored symbols. Each point represents the median of a minimum of 3 quantified biopsies per participant. Following repeated-measures and linear mixed-effects (lme) analyses, post-hoc lme contrasts and pairwise nonparametric (Wilcoxon) tests were performed. Benjamini-Hochberg adjusted P values are reported.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts